Image -1 (B55cec96 C673 44ee 8ea7 3465f7bc8e67 01)
Sildenafil
Product Images NDC 50090-5802
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 50090-5802). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image-2 (B55cec96 C673 44ee 8ea7 3465f7bc8e67 02)
The text contains a table with the systolic blood pressure readings (in mmHg) for a pre-dose condition and different time points post-dose (in hours) for two treatments- 6-O Sildenafil 100mg and Placebo. No further information is available.*
Image-3 (B55cec96 C673 44ee 8ea7 3465f7bc8e67 03)
This is a table showing the change in SBP (Systolic Blood Pressure) in mmHg over time postdose in hours. The treatment groups are represented by two columns: OseDoxazosin + Placebo and OseDoxazosin + Sildenafil 25mg. The values for change in SBP are 20 mmHg, -30 mmHg, and 40 mmHg. The time postdose is represented by four rows: 3, 5, [, and 7 hours.*
Image-4 (B55cec96 C673 44ee 8ea7 3465f7bc8e67 04)
Image-5 (B55cec96 C673 44ee 8ea7 3465f7bc8e67 05)
This appears to be a table that possibly shows the effects of a drug combination. It includes the blood pressure measurement "mmHg" and has two drug combinations listed: "Doxazosin + Sidenafil 100 mg" and "Doxazosin + Placebo". The numbers 1-3 and 5-8 may refer to measurements taken at different time intervals after dosing. Without additional context, it is difficult to determine the specific meaning or significance of the information presented.*
Image-6 (B55cec96 C673 44ee 8ea7 3465f7bc8e67 06)
The text describes a graph indicating the plasma concentration in ng/mi over time post-dose (in hours) for a commercial tablet. The graph shows a peak concentration of 450 ng/mi at around 12 hours post-dose, with a steady decrease in concentration over time. At 18 hours post-dose, the concentration has fallen to around 350 ng/mi. The graph also appears to show that at 3 hours post-dose, the concentration is around 20 ng/mi, and at 20 hours post-dose, the concentration is around 2-2.5 ng/mi.*
Image-7 (B55cec96 C673 44ee 8ea7 3465f7bc8e67 07)
Image-8 (B55cec96 C673 44ee 8ea7 3465f7bc8e67 08)
Image-9 (B55cec96 C673 44ee 8ea7 3465f7bc8e67 09)
The text appears to be showing some numerical data related to a medical study or clinical trial. It lists different dosages of three drugs with letters and symbols denoting some percentages and probabilities. The drugs are named Placebo, Sildenafi, Sidenafl, and Sidenafil. There are also counts of patients in different treatment groups. The only clear information is that the overall treatment has a p-value of less than 0.0001, which can indicate strong evidence of an effect.*
Label Image (Lbl500905802)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
